Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04392622 · ClinicalTrials.gov registry record · Phase 1

d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC

A Phase 1 study of Xerostomia, sponsored by Stanford University.

Recruiting
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT04392622: Recruiting Phase 1 study of Xerostomia, sponsored by Stanford University.

NCT04392622 is a Phase 1 study of Xerostomia that is actively recruiting participants, run by Stanford University. The registered enrollment target is 40 participants, below the 92-participant average among 13 other Xerostomia trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04392622, a Phase 1 study of Xerostomia, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This study explores the safety of d-limonene, a commercially-available dietary supplement (food) as a potential therapeutic for the severe dry mouth (xerostomia) experienced by patients with head and neck cancer as a side effect of their anti-cancer treatment.

Primary Outcome

Dose limiting toxicity is defined as d-limonene related toxicity causing: * Greater than 1 week delay in completing the radiation course. * Inability to receive ≥ 66 Gy of radiotherapy. * Inability to receive at least 200 mg/m2 of total cisplatin equivalent dose or a total area under the curve (AUC) of 10 for carboplatin equivalent dose due to toxicity related to d-limonene Grade 3 or higher diarrhea that is attributable to the study drug. * Grade 3 abdominal pain that is attributable to the st

Conditions Studied

Interventions

  • DRUG Cisplatin
  • DRUG D-Limonene Gelcaps
  • RADIATION Intensity modulated radiotherapy (IMRT)
  • OTHER Xerostomia questionnaire

Study Locations (1)

California

  • Stanford University - Stanford

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2021-02-15
Est. Completion 2028-05-15
Phase Phase 1
Stanford University

1,744 total trials

What NCT04392622 shows while recruiting

NCT04392622 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 92-participant average among 13 other Xerostomia trials with a reported enrollment target (57% lower).

The record links to 1 condition, with Xerostomia appearing as the primary indexed condition, and to 4 interventions - of which Cisplatin is the first listed.

NCT04392622 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04392622 about?

NCT04392622 is a clinical study titled "d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC". This study explores the safety of d-limonene, a commercially-available dietary supplement (food) as a potential therapeutic for the severe dry mouth (xerostomia) experienced by patients with head and neck cancer as a side effect of their anti-cancer treatment.

What is the current status of trial NCT04392622?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2021-02-15. Estimated completion is 2028-05-15.

What conditions does trial NCT04392622 study?

This clinical trial studies the following conditions: Xerostomia.

What interventions are being tested in trial NCT04392622?

The interventions under investigation include: Cisplatin (DRUG), D-Limonene Gelcaps (DRUG), Intensity modulated radiotherapy (IMRT) (RADIATION), Xerostomia questionnaire (OTHER).

Who is sponsoring clinical trial NCT04392622?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04392622 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Xerostomia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04392622's enrollment target sits among peer trials

40 8th of 13 higher than 5 of 13 other Xerostomia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Xerostomia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04392622, the US trial registry maintained by the National Library of Medicine. NCT04392622 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.